The world leader in CTPS1 inhibition for the targeted treatment of cancer.
A new approach with the potential to yield a highly selective, safe and effective cancer treatment for both blood cancers and solid tumours.
Our lead asset, STP938 is a first-in-class, highly selective, orally bioavailable, targeted oncology therapy that aims to become a key drug for a multitude of cancer treatment regimens.
Current Cancer Treatment
Every 3 minutes someone is diagnosed with leukemia, lymphoma or myeloma in the US
There are over a hundred different types of blood cancer
No improvement in 5-year survival rates for peripheral T cell lymphoma patients in the past 20 years
Watch the leadership team discuss our lead CTPS1 inhibitor STP938
STP938 is entering clinical trials for the treatment of blood cancers with the potential for accelerated approval from a single arm Phase II study.
Our lead CTPS1 inhibitor STP938 has the potential to become a key treatment for a multitude of cancers and has recently entered clinical development for the treatment of blood cancers, with the potential for accelerated approval from a single arm Phase II Study. STP938 could also form the backbone of various treatment regimens for solid tumors.
15 rue Louis et Auguste Lumière
Technoparc du Pays-de-Gex